Equity Upgrades and Downgrades on Wall Street Nov. 22nd: DLB, NVDA, LGCY, VRUS, GILD, POL, SHLM

Wall St. Watchdog reveals information about companies for which stock analysts either upgraded or downgraded the shares on November 22nd.

Upgrades

  • Dolby Labs (NYSE:DLB): Barrington Research upgraded its rating on this company from Mkt Perform to Outperform and changed its price target to $43. About the company: Dolby Laboratories Inc. develops audio signal processing systems for the motion picture, broadcasting, and music recording industries, as well as the consumer market. Get the most recent company news and stock data here >>
  • NVIDIA (NASDAQ:NVDA): Needham upgraded its rating on this company from Underperform to Buy and changed its price target to $18. About the company: NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company’s products provide interactive 3D graphics to the mainstream personal computer market. Get the most recent company news and stock data here >>
  • WGL Holdings (NYSE:WGL): Brean Murray upgraded its rating on this company from Hold to Buy and changed its price target to $48. About the company: WGL Holdings Inc., through its Washington Gas Light Company subsidiary, sells and delivers natural gas and other energy-related products and services. The Company serves residential, commercial, and industrial customers throughout metropolitan Washington, D.C. and the surrounding region. Get the most recent company news and stock data here >>
  • Legacy Reserves (NASDAQ:LGCY): Robert W. Baird upgraded its rating on this company from Neutral to Outperform and changed its price target to $31. About the company: Legacy Reserves acquires and explores for oil and natural gas properties in the United States. Get the most recent company news and stock data here >>

Downgrades

  • Pharmasset (NASDAQ:VRUS): Brean Murray downgraded its rating on this company from Buy to Hold. Canaccord Genuity downgraded its rating on this company from Buy to Hold. About the company: Pharmasset, Inc. is a pharmaceutical company. The Company develops oral therapeutics for the human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV). Get the most recent company news and stock data here >>
  • Gilead Sciences (NASDAQ:GILD): Summer Street Research downgraded its rating on this company from Buy to Neutral. About the company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions. Get the most recent company news and stock data here >>
  • PolyOne (NYSE:POL): Longbow downgraded its rating on this company from Buy to Neutral. About the company: PolyOne Corporation is an international polymer services company with operations in North America, Europe, Asia, Australia, and South America. The Company provides thermoplastic compounds, specialty resins, specialty polymer formulations, engineered films, and color and additive systems. PolyOne also conducts operations in rubber compounding and thermoplastic resin distribution. Get the most recent company news and stock data here >>
  • A. Schulman (NASDAQ:SHLM): Longbow downgraded its rating on this company from Buy to Neutral. About the company: A. Schulman, Inc. supplies plastic compounds and resins which are used as raw materials by its customers. The Company combines basic resins purchased from basic resin producers and enhances them with additives. Schulman generally produces compounds to meet customer requirements and on the basis of customer commitments, but also buys and then resells prime and off-grade plastic resins. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet